Heart surgery is done to correct problems with the heart. More than half a million heart surgeries are done each year in the United States for a variety of heart problems. Heart surgery is used to correct heart problems in children and adults. This article discusses heart surgeries for adults. For more information about heart surgeries for children, see the Diseases and Conditions Index articles on congenital heart defects, holes in the heart, and tetralogy of Fallot.
The most common type of heart surgery for adults is coronary artery bypass grafting (CABG). During CABG, surgeons use healthy arteries or veins taken from another part of the body to bypass (that is, go around) blocked arteries. CABG relieves chest pain and reduces the risk of heart attack.
Identification of a molecular communications pathway that influences the mobilization of hematopoietic (blood) stem cells could lead to targeted therapies for improving bone marrow transplant success rates.
NewYork-Presbyterian Hospital/Columbia University Medical Center today announced the opening of The Carmen and John Thain Center for Prenatal Pediatrics. The new unit will provide high-risk pregnant women and their babies the most comprehensive care currently available, all in one location.
Just released data from a clinical trial shows promise for a new minimally invasive treatment option for patients with severe aortic stenosis who are too sick for traditional forms of open-heart surgery. As compared to standard medical therapy, the new procedure, transcatheter aortic valve implantation (TAVI), significantly reduced mortality rates in patients who received the new valve.
One-year data from the PARTNER clinical trial, published today in the New England Journal of Medicine, demonstrate that transcatheter aortic-valve implantation, compared with standard therapy, resulted in significantly lower rates of death among patients who cannot undergo surgery for aortic stenosis. The results will be presented tomorrow as a Late Breaking Trial at the 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced enrollment of the first patient in the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) trial which is designed to assess patient outcomes using a standardized, best practices approach in endoscopic vessel harvesting (EVH) for coronary artery bypass graft surgery (CABG) compared with open vein harvesting methods.
Implantation of a new bioprosthetic-tissue valve into the hearts of patients who have severe aortic stenosis and are too sick or too old for open-heart surgery has been found to both save lives and improve the quality of those lives, according to a new multicenter study, to be published online at 2 p.m. Pacific time today in the New England Journal of Medicine.
While aging impacts everyday living in many ways, the latest technologies in the medical, consumer and lifestyle fields have the potential to help older adults live better for longer.
The Virginia Commonwealth University Medical Center is the lead institution in a national clinical trial of technology that will allow artificial heart patients to recuperate, rehabilitate and wait in the comfort of their own homes until a donor heart becomes available for transplant.
Using a newly FDA approved pulmonary valve, Dr. Frank Ing, director of the catheterization laboratory at Texas Children's Hospital and his team of pediatric interventional cardiologists implanted a transcatheter pulmonary heart valve into the heart of a 13-year-old girl, which spared her from having her chest opened for a third heart surgery.
Medtronic, Inc. today announced CE Mark approval and the first global use and launch of the Medtronic CoreValve® delivery system with AccuTrak™ Stability Layer for transcatheter aortic valve implantation (TAVI). AccuTrak's proprietary technology allows physicians to achieve enhanced control and accuracy in the deployment of the CoreValve device.
The European Society of Cardiology (ESC) today announces the release of new Clinical Practice Guidelines covering the management of Grown-up Congenital Heart Disease (GUCH). More than two million adults in Europe are assumed to be affected by the condition, and the numbers are growing as a consequence of sharply increased survival rates due to advances in paediatric cardiology and heart surgery.
Scientists have identified a genetic basis for determining the severity of allergic asthma in experimental models of the disease.The study may help in the search for future therapeutic strategies to fight a growing medical problem that currently lacks effective treatments, researchers from Cincinnati Children's Hospital Medical Center report in the Aug. 29 Nature Immunology.
When Doris Snyder celebrated her 102nd birthday on August 10, she was that much closer to the expected birth of her first great-granddaughter who's due to arrive early September. She is very excited about the milestone, which might not have been possible were it not for a cutting-edge, experimental procedure that replaced one of Doris' heart valves weeks earlier when she was 101. The valve had been rendered useless by aortic valve stenosis—hardening from calcium deposits that restrict the flow of blood from the heart.
Octapharma AG, one of the largest private manufacturers of plasma products in the world, announced today that the clinical development for Uniplas® has been successfully completed. The product has been filed for registration in Europe and will be submitted later in the USA.
Three-dimensional MRI is an emerging and useful technique for displaying fetal anatomy and diagnosing problems in the womb in a wide spectrum of clinical applications, according to Jeffrey C. Hellinger, M.D., a pediatric imaging specialist at Stony Brook University Medical Center.
Cardiac allograft vasculopathy (CAV), also known as chronicle rejection, is a leading cause of graft (foreign heart) loss and death in patients who survive the first year after heart transplantation. The typical pathological change of CAV is gradually thickening of coronary wall in "foreign" heart due to continuous immunological reaction between donated heart and the host. In some cases, undetected CAV may silently cause graft failure with global myocardial ischemia without any documented infarction signs. Thus, continually monitoring development of asymptomatic CAV is important for selecting prophylactic strategies to get better prognosis. However, most current examinations of detecting CAV are invasive and with certain risks.
An Ohio Federal Court of Appeals ruling issued yesterday is reinstating the late victim's claim that the recalled diet drug Redux (commonly called fen-phen) linked to her death should never have been marketed to the American people by Wyeth due in part to its pre-approval concerns about potentially lethal side effects.
Age alone should not determine surgical risk in a person age 80 or over, according to expert commentary from Mark Katlic, M.D., director of Thoracic Surgery at Geisinger Wyoming Valley Medical Center in Wilkes-Barre, Pa. Dr. Katlic's commentary complements a McGill University Health Science Center trend study, appearing in this week's edition of the Canadian Medical Association Journal (CMAJ). The study finds an increase in coronary artery bypass grafts (CABGs) and percutaneous coronary interventions (PCIs) with better results in people previously believed to be too old for these procedures.
A newer, less invasive method of heart valve replacement shows promise and may be appropriate for patients who cannot tolerate traditional open heart surgery, but research is needed to understand its potential risks and benefits, according to a new study funded by HHS' Agency for Healthcare Research and Quality.
School-aged children who undergo cardiopulmonary bypass (CPB) during surgery for less complicated congenital heart defects do not appear to suffer any impairments in neurocognitive abilities, such as intelligence, memory, motor skills and behavior.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.